June 2017 Headline Industrial Production Improves
Jul 14, 2017Jeremy Parkinson0
The headlines say seasonally adjusted Industrial Production (IP) was up. The manufacturing segment of industrial production improved. Analyst Opinion of Industrial Production The market expected improvement this month in industrial production. Our analysis shows this month was significantly weaker than last month BUT the best way to view this is the 3 month rolling averages […]
USD/CAD Forming A Double Bottom After The Poor Us Data
Jul 14, 2017Jeremy Parkinson0
Everything is going against USD/CAD. The big mover of the week came from Ottawa. The Bank of Canada not only raised rates but also made hawkish sounds. They are set to hike rates again this year, based on upgraded forecasts. The dollar side is also making its contribution. The troubles of Trump Junior were joined by Janet Yellen’s nod […]
BoJ Bond Buying And Gold
Jul 14, 2017Jeremy Parkinson0
Last week, the Bank of Japan offered to buy an unlimited amount of JGBs. What does it mean for the gold market? After Draghi’s speech at the end of June, many significant central banks turned more hawkish. However, the shift does not apply to the Bank of Japan. On Friday, the BoJ, in a special market operation, offered […]
Gold & Silver; 16-Year Bull Market Support Test In Play, Says Joe Friday
Jul 14, 2017Jeremy Parkinson0
Below compares the performance of Gold, Silver and the S&P 500 since July of 2001. Why compare the performance of the three starting in 2001? This is when Gold & Silver created a series of higher lows, starting a new bull market that lasted the following decade. From 2001 until 2011, Gold & Silver both outperformed […]
Commodities: Oil Update
Jul 14, 2017Jeremy Parkinson0
It may not be on your economic calendar, but on July 24 OPEC meets in St. Petersburg, and there is a reasonably good chance that efforts to bring Libya and Nigeria into the quota system may succeed. According to a report from the OPEC Secretariat that draws on secondary sources (apparently national sources are not […]
CyberArk Software Shares Crash As Company Posts Disappointing Guidance Numbers
Jul 14, 2017Jeremy Parkinson0
CyberArk Software Ltd. (CYBR), a global software-based IT security solutions yesterday reported their preliminary second quarter 2017 financial results. CyberArk reported that they expect second quarter revenues to be in between $57 to $57.5 million which is down from previous guidance of $61 to $62 million. CyberArk Software Ltd. CEO’s Comments “We are disappointed that our […]
Banks Down, Market Wants Upward Follow Through On Darvas Breakout
Jul 14, 2017Jeremy Parkinson0
Out of the Darvas Box – just barely though Okay, so we have been here before. This almost-two month long box that the S&P 500 has been trading in has been broken for only the second time, yesterday. The last time it broke was on June 19th, and the following day resulted in a huge […]
SPX Cycles, Fed Funds And Gold
Jul 14, 2017Jeremy Parkinson0
This “amateur cyclist’s” chart (I am anything but a cycles analyst) of the S&P 500 shows that the 12 month marker (C12) meant exactly nothing as the market remained firmly on trend, after brief pokes down in April and May. We noted that C12 was a lesser indicator than the 30 month cycle, which has coincided with some pretty significant […]
Better Dividend Aristocrat: Sherwin-Williams Or PPG?
Jul 14, 2017Jeremy Parkinson0
PPG Industries (PPG) is a Dividend Aristocrat. It has increased its dividend for 44 years in a row, which is certainly an impressive feat. That said, there may be a better Dividend Aristocrat to buy, and it happens to be one of PPG’s biggest competitors. Sherwin-Williams (SHW) has 38 consecutive years of dividend increases under […]
Biotech Digest – FMI Inks New Deal, SGMI Gets Fast Track Designation, ANTM Files A Suit
Jul 14, 2017Jeremy Parkinson0
Top Pick of the Day: FMI Foundation Medicine Inc. (Nasdaq: FMI) announced inking a new deal with Kura Oncology for supporting enrollment in its its Phase 2 clinical trial evaluating farnesylation inhibitor tipifarnib in patients with treatment-resistant HRAS-mutant squamous cell carcinoma of the head and neck (SCCHN). Under the terms of the collaboration, Foundation Medicine’s […]